Advertisement
"We appreciate the invitation by SABPA to interface with a large audienceof industrial professionals, entrepreneurs and healthcare investment funds,"said Dr. James J. Tong, Chief Financial Officer and Chief Business &Development Officer of Tianyin, "Since 2005, SAPBA conferences have been theforefront to bridge biopharmaceuticals and innovations between the healthcareindustry of US and China. We look forward to the in-depth interaction with thebiopharmaceutical community in US."
Advertisement
Dr. Jiang, Guoqing, Chairman and CEO of Tianyin Pharmaceutical pointed out,"The past 10 years have seen the rapid expansion of China health care industry,propelled by the economic growth in China, favorable government policies andaccelerated demands for pharmaceuticals resulted from an increasingurbanization of a growing population. The ongoing healthcare reform providesfurther momentum for both generic medicines as well as innovativebiopharmaceuticals. Tianyin is positioned to explore the opportunities on bothfronts."
SAPBA meeting on 24th of April, McDonald Auditorium, University ofCalifornia, Irvine from 8:30 am till 4:30 pm (http://www.sabpa.org/web/OCLA/)
About Tianyin Pharmaceuticals
Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, SichuanProvince of China, is a leading biopharmaceutical company that is engaged inthe development, manufacturing, marketing and sale of modernized traditionalChinese medicines and branded generics, equipped with two state-of-the-artmanufacturing facilities and an extensive nationwide sales and distributionnetwork throughout China. Tianyin currently manufactures and markets acomprehensive portfolio of 50 products, of which 22 are listed in the highlyselective National Medicine Catalog of the National Medical Insurance program,7 are included in the essential drug list of China. Tianyin achieved 10 newdrug approvals at SFDA in 2009 and has a pipeline of 12 products pendingregulatory approval that target various indications with considerable marketpotential. Tianyin has an extensive nationwide distribution network with asales force of 720 sales representatives out of totaled 1,365 employees. Formore information about Tianyin, please visit http://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.For more information, please contact: Investors Contact: James Jiayuan Tong M.D. Ph.D. Chief Financial Officer, Chief Business & Development Officer Director Tianyin Pharmaceutical Co., Inc. Web: http://www.tianyinpharma.com Email: [email protected] Tel: +86-28-8551-6696 +1-949-350-6999 (U.S.) Address: 23rd Floor Unionsun YangKuo Plaza No 2 Block 3 South Renmin Road Chengdu, 610041 China
SOURCE Tianyin Pharmaceutical Co., Inc.
